@article{Suleman_Shah_2014, title={The improvement in the ABI index following 3 month treatment with cilostazol in patients with mild to moderate peripheral arterial disease}, volume={28}, url={https://www.jpmi.org.pk/index.php/jpmi/article/view/1534}, abstractNote={<p class="Pa8"><strong>Objective: </strong>To study the effects of cilostazol in patients with mild to moder­ate peripheral arterial disease (PAD) using the improvement in ankle brachial pressure index (ABI).</p> <p class="Pa8"><strong>Methodology: </strong>This hospital based interventionist study was a prospective, open labeled clinical trial. After the baseline data collection cilostazol was given to the group A, while the group B didn’t receive cilostazol. The effect of intervention was noted at the timed study points at 4, 6 and 12 weeks .The antiplatelets were used in the group B as a control.</p> <p class="Pa8"><strong>Results: </strong>The ABI improvement at the end of the study in the cilostazol treated group was marked compared with the control group. The group A had 65 males and 35 females, while the group B had 74 males and 26 females. The total ABI improved in the right and left lower limb with a P value of 0.001 each. The ABI results were better in the male, diabetic and hypertensive subsets of study as compared with female, obese and smoker.</p> <p class="Pa8"><strong>Conclusion: </strong>Cilostazol significantly improves ABI in PAD. Its use in the indicat­ed population group should be encouraged to improve the management and prevent the complications.</p>}, number={3}, journal={Journal of Postgraduate Medical Institute}, author={Suleman, Shams and Shah, M Abid}, year={2014}, month={Jul.} }